Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLT3 Ligand Immunotherapy and SBRT for Advanced NSCLC
NCT02839265Phase 2Completed
- Sponsor
- Montefiore Medical Center
- Start
- Jul 2016
- Primary completion
- Oct 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of Flt3 ligand in non-small cell lung cancer (NSCLC), sponsored by Montefiore Medical Center. Started Jul 2016; status: completed.
02
Drugs
Flt3 ligand
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02839265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839265.